Barriers and challenges in integration of anthroposophic medicine in supportive breast cancer care

被引:2
作者
Ben-Arye, Eran [1 ,2 ]
Schiff, Elad [3 ,4 ]
Levy, Moti [5 ]
Raz, Orit Gressel [1 ,5 ]
Barak, Yael [1 ,5 ]
Bar-Sela, Gil [6 ]
机构
[1] Clalit Hlth Serv, Integrat Oncol Program, Oncol Serv, Lin Med Ctr, IL-35152 Haifa, Israel
[2] Technion Israel Inst Technol, Fac Med, Dept Family Med, Complementary & Tradit Med Unit, Haifa, Israel
[3] Bnai Zion Hosp, Dept Internal Med & Integrat Surg Serv, Haifa, Israel
[4] Int Ctr Hlth Law & Eth, Haifa, Israel
[5] Clalit Hlth Serv, Clalit Complementary Med, Haifa, Israel
[6] Rambam Hlth Care Campus, Div Oncol, Haifa, Israel
来源
SPRINGERPLUS | 2013年 / 2卷
关键词
Integrative medicine; Anthroposophic medicine; Viscum album; Quality of life; Complementary medicine; Cancer; QUALITY-OF-LIFE; VISCUM-ALBUM-L; COMPLEMENTARY MEDICINE; MISTLETOE; EXTRACT; ONCOLOGY; SAFETY; CHEMOTHERAPY; MULTICENTER; THERAPY;
D O I
10.1186/2193-1801-2-364
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In the last decade, more and more oncology centers are challenged with complementary medicine (CM) integration within supportive breast cancer care. Quality of life (QOL) improvement and attenuation of oncology treatment side effects are the core objectives of integrative CM programs in cancer care. Yet, limited research is available on the use of specific CM modalities in an integrative setting and on cancer patients' compliance with CM consultation. Studies are especially warranted to view the clinical application of researched CM modalities, such as anthroposophic medicine (AM), a unique CM modality oriented to cancer supportive care. Our objective was to characterize consultation patterns provided by physicians trained in CM following oncology health-care practitioners' referral of patients receiving chemotherapy. We aimed to identify characteristics of patients who consulted with AM and to explore patients' compliance to AM treatment. Of the 341 patients consulted with integrative physicians, 138 were diagnosed with breast cancer. Following integrative physician consultation, 56 patients were advised about AM treatment and 285 about other CM modalities. Logistic multivariate regression model found that, compared with patients receiving non-anthroposophic CM, the AM group had significantly greater rates of previous CM use [EXP(B) = 3.25, 95% C. I. 1.64-6.29, p = 0.001] and higher rates of cancer recurrence at baseline (p = 0.038). Most AM users (71.4%) used a single AM modality, such as mistletoe (viscum album) injections, oral AM supplements, or music therapy. Compliance with AM modalities following physician recommendation ranged from 44% to 71% of patients. We conclude that AM treatment provided within the integrative oncology setting is feasible based on compliance assessment. Other studies are warranted to explore the effectiveness of AM in improving patients' QOL during chemotherapy.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 32 条
  • [21] The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients
    Kovacs, E
    [J]. PHYTOTHERAPY RESEARCH, 2002, 16 (02) : 143 - 147
  • [22] Kroz M, 2012, INTEGR CANC THER
  • [23] European and Oriental mistletoe: From mythology to contemporary integrative cancer care
    Lev, Efraim
    Ephraim, Marco
    Ben-Arye, Eran
    [J]. EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2011, 3 (03) : E133 - E137
  • [24] Adjuvant simultaneously mistletoe/chemotherapy for breast cancer - Effect of immune parameter, quality of life and compatibility
    Loewe-Mesch, Annette
    Kuehn, Juergen J.
    Borho, Karin
    Abel, Ulrich
    Bauer, Carmen
    Gerhard, Ingrid
    Schneeweiss, Andreas
    Sohn, Christof
    Strowitzki, Thomas
    v. Hagens, Cornelia
    [J]. FORSCHENDE KOMPLEMENTARMEDIZIN, 2008, 15 (01): : 22 - 30
  • [25] A cytotoxic diarylheptanoid from Viscum cruciatum
    Martín-Cordero, C
    López-Lázaro, M
    Agudo, MA
    Navarro, E
    Trujillo, J
    Ayuso, MJ
    [J]. PHYTOCHEMISTRY, 2001, 58 (04) : 567 - 569
  • [26] Mengs U, 2002, ANTICANCER RES, V22, P1399
  • [27] Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review
    Ostermann, Thomas
    Raak, Christa
    Buessing, Arndt
    [J]. BMC CANCER, 2009, 9
  • [28] Piao BK, 2004, ANTICANCER RES, V24, P303
  • [29] Semiglazov VF, 2006, ANTICANCER RES, V26, P1519
  • [30] Söllner W, 2000, CANCER-AM CANCER SOC, V89, P873, DOI 10.1002/1097-0142(20000815)89:4<873::AID-CNCR21>3.0.CO